Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting β2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma therapy ...
Mylan N.V. has announced that it has launched the first bioequivalent alternative to GlaxoSmithKline's Seretide® Evohaler® (salmeterol xinafoate/fluticasone propionate) under the brand name Sirduplaâ„¢ ...
3.1 ICSs suppress inflammation in the lungs and are recommended for prophylactic treatment of asthma. In the UK, three ICSs are licensed for use in children: beclometasone dipropionate, budesonide and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback